CFN Media Group posted an article and video interview of United Cannabis Corp (OTCMKTS:CNAB) CEO highlighting company’s award winning line of cannabis therapies and innovative approach to medicinal marijuana use.
The changing scenario
United Cannabis has developed a comprehensive line-up of cannabinoids that are approved to manage dispensaries. As per the latest update, the A.C.T. Now strategy is meant to help patients opt for cannabinoids for therapeutic purposes. These offering and services are designed to reduce the gap between providing official access to cannabis and helping people effectively treat grave medicinal conditions.
Prana Bio Medicinal CBD offerings use a patent-pending infusion procedure using select lipids, fatty acids and specific combinations of cannabis-based terpenes to enhance bioavailability. The capsules are enveloped in sealed blister packs for a regimen of 10-30-60 day and are made with full-spectrum, such as whole plant, cannabis derived terpenes with distinct percentages of CBD and THC.
As per the complementary A.C.T. Now service with Prana Bio Medicinal buys, the same is apportioned to a nurse that will weigh his or her current drugs and create a tailored program for them. The people then depend on a promising HIPPA-compliant cloud-dependent software to take a note of their health conditions, planned follow-ups, and fine-tuning of programs with their apportioned health professional.
Earnest Blackmon and Tony Verzura, United Cannabis’ CEO and CTO respectively, have been involved with application of medical cannabis since it was decriminalized in California in 1999. After the decriminalization of medical cannabis, the emphasis was moved to Colorado. The team has over 30 years of total combined experience in the market, including engineered facilities, regulatory compliance, security, manufacturing, genetics, cultivation, branding, retail and extraction operations.
In the last trading session, the stock price of United Cannabis declined more than 7% to close the day at $1.03. The decline came at a share volume of 331,703 compared to average share volume of 253,550.
2017 Most Disruptive Biotech VBIOhttp://www.financialstrend.com
Disruptive biotech VBIO decodes targeted drug delivery for stem cells
Can CBD Oil Get Rid of Chronic Pain?http://www.greenleaf.farm
Pure Colorado Golden CBD Oil Hemp Extracts
Top Stock Analysis At Journal Transcripthttp://www.journaltranscript.com
Early bird alerts on the hottest OTC companies
Wall Street PR - BIG BUYOUT OPPORTUNITYhttp://wallstreetpr.com
Here’s how to leverage this breakthrough technology…
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure